Please login to the form below
Horizant
This page shows the latest Horizant news and features for those working in and with pharma, biotech and healthcare.
US shortage of GSK’s restless legs syndrome treatment Horizant
FDA blames contract manufacturer delays. Delays at GlaxoSmithKline's (GSK) contract manufacturer have caused a shortage in the US of restless legs syndrome treatment Horizant, according to the FDA. ... Then in November 2012, GSK and XenoPort agreed to
Latest news
-
GSK sales fall for first quarter of 2011
Recent approvals for GSK include lupus drug Benlysta (belimumab), Horizant (gabapentin enacarbil) for Restless Legs Syndrome and epilepsy treatment Trobalt (retigabine).
-
GSK Restless Legs Syndrome drug approved
GlaxoSmithKline and XenoPort have won marketing approval from the US Food and Drug Administration for Horizant, a treatment for moderate-to-severe primary Restless Legs Syndrome. ... Horizant's approval for the condition was based on two 12-week clinical
-
FDA rejects GSK and Xenoport's Horizant
GSK and XenoPort, have received a Complete Response letter from the US FDA relating to Horizant (gabapentin enacarbil). ... Horizant is developed from a variant of Pfizer's Nerontin (gabentin), used to control seizures in epilepsy patients.
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Deal Watch May 2016
399-616. Xenoport/ Arbor Pharmaceuticals. Corporate acquisition. Acquisition for $7.03 per share [60% premium]; includes Horizant [gabapentin] for restless legs.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
XenoPort appoints chief medical officer
Dr Kim has been with the US biopharma company since July 2013, when he joined as VP of medical affair, supporting the marketing of Horizant (gabapentin enacarbil) in restless legs syndrome
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Head of Partnerships - Competitive - London
-
Competitive Salary Offered
-
Senior Medical Writer
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Midweight Brand Planner
-
Up to £50, 000
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
Subscribe to our email news alerts
- Verily unveils next-gen trials alliance with Novartis, Pfizer
- Syncona launches another cell therapy company, Treg specialist Quell
- Keytruda monotherapy fails in triple negative breast cancer
- Moving annual total (MAT)
- Europe responding to gene therapy challenge, but picture remains fragmented
- Key success factor (KSF)
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Playing Mind Games
- To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
- PM Society Digital Award Finalists
- P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
- The Exhibition Hall: Past, Present and Future
- As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Quick links
Infographics
